Clinical Trial Update: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating oral azacitidine versus investigator's choice therapy in relapsed or refractory angioimmunoblastic T-cell lymphoma, reporting efficacy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• Oral azacitidine (azacitidine (oral formulation))

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma | Phase 3 | Status: COMPLETED